IRIS
CEA, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.009
Totale 10.009
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 10.009
Totale 10.009
Salva come PNG Salva come JPEG
Città #
Genova 6.889
Genoa 1.332
Rapallo 1.101
Vado Ligure 666
Bordighera 21
Totale 10.009
Salva come PNG Salva come JPEG
Nome #
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. 181
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of AKT-mediated gene repression 178
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 173
Autophagy in blood cancers: biological role and therapeutic implications. 172
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 170
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 167
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 165
SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells 158
APO866 activity in hematologic malignancies: a preclinical in vitro study. 157
Ras-induced resistance to lapatinib is overcome by MEK inhibition 149
Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. 147
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival 145
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 144
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 143
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 143
Sirt6 regulates dendritic cell differentiation, maturation, and function 140
Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells 140
SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects 139
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 138
Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response 137
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis 134
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 133
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition. 132
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 132
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition 131
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma 129
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation 127
Evaluation of prognostic indices in elderly hospitalized patients 125
Synthesis of Pyrrolidine 3,4-Diol Derivatives with Anticancer Activity on Pancreatic Tumor Cells 124
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 124
New insights into biology of chronic myeloid leukemia: implications in therapy. 123
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 122
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 121
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 119
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 118
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 116
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 116
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 113
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 112
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. 110
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 109
Synthesis and cancer growth inhibitory activities of 2-fatty-alkylated pyrrolidine-3,4-diol derivatives 108
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. 107
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 106
Biological Insights into Myeloma and Other B Cell Malignancies 106
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 106
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 106
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 105
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 104
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 104
Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8 103
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. 100
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. 100
Catastrophic NAD+ Depletion through Nampt Inhibition in Activated T Lymphocytes Reduces Demyelination and Disability in EAE. 98
Targeting Inflammation in Primary Cardiovascular Prevention 96
Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: Added value of a Radiomics approach 95
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 94
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 94
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 91
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 91
null 91
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. 90
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 90
Abstract CT075: Fasting-mimicking diet and hormone therapy modulates metabolic factors to promote breast cancer regression and reduce side effects 88
Nutrients in the Prevention of Alzheimer's Disease 87
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 86
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 85
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 84
Radiomics and artificial intelligence analysis of CT data for the identification of prognostic features in multiple myeloma 81
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 78
Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. 77
Safety and feasibility of fasting‐mimicking diet and effects on nutritional status and circulating metabolic and inflammatory factors in cancer patients undergoing active treatment 74
Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model 70
The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells 69
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 69
Radiomics and artificial intelligence for outcome prediction in multiple myeloma patients undergoing autologous transplantation: A feasibility study with ct data 69
SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice 66
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 64
Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. 63
Depletion of the intracellular coenzyme NAD plus in activated T-cells ameliorates experimental autoimmune encephalomyelitis 63
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 62
null 61
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 59
Harnessing Immune Response in Acute Myeloid Leukemia 56
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 56
Chronic myeloid leukemia: Reaching for the cure 52
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 52
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 51
Nicotinic acid phosphoribosyltransferase is overexpressed in solid tumors and regulates cancer cell metabolism and susceptibility to FK866 45
Resistin, oxidative stress and amyloid beta: a possible link in Alzheimer' disease 43
The non-coding RNA landscape of plasma cell dyscrasias 42
Cyclic fasting bolsters cholesterol biosynthesis inhibitors' anticancer activity 40
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 40
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 39
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent 38
Effect of Geriatric Comanagement in Older Patients Undergoing Surgery for Gastrointestinal Cancer: A Retrospective, Before-and-After Study 37
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial 31
Targeting the deacetylase SIRT6 unveils spliceosome deregulation as exploitable vulnerability for aggressive myeloma 30
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 30
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery 30
Totale 10.008
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.692
article - articoli 35.009
book - libri 0
conference - conferenze 683
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.384
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.149 0 0 0 0 277 333 379 204 260 353 260 83
2020/20211.024 57 87 104 79 107 64 70 90 84 116 97 69
2021/20221.260 44 63 100 157 63 103 70 249 73 112 63 163
2022/20231.391 147 155 17 142 231 179 9 83 200 28 177 23
2023/20241.013 37 94 33 146 96 182 80 96 31 21 73 124
2024/2025762 125 187 63 238 149 0 0 0 0 0 0 0
Totale 10.322